Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China - Poll - MDSpire

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China

  • By

  • Wei Jiang

  • Wei Zhong

  • Jingdi Yu

  • Yufei Tang

  • Qunyi Guo

  • June 18, 2026

  • 0 min

Share

Original Source(s)

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China

  • by Wei Jiang, Wei Zhong, Jingdi Yu, Yufei Tang, Qunyi Guo

  • June 18, 2026

Related Content

Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation

Differential expression of immune activation markers in T cells from patients with multiple myeloma

Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis